A study on non-T-cell depleted haploidentical bone marrow transplantation using Basiliximab for GVHD prophylaxis
- VernacularTitle:达利珠单抗在未去T淋巴细胞单倍体相合的骨髓移植中的应用
- Author:
Huiren CHEN
;
Shuquan JI
;
Hengxiang WANG
- Publication Type:Journal Article
- Keywords:
Immunosuppressive agents;
Bone marrow transplantation;
Graft vs host disease
- From:
Chinese Journal of Organ Transplantation
1996;0(03):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the effects of Basiliximab (Simulect) on reducing the incidence of severe acute GVHD in haploidentical bone marrow transplantation (BMT). Methods Nine patients with leukemia received haplotype Allo-BMT from HLA two or three loci mismatched related donor. Most patients were classified as high risk category. The donors of patients were administrated with G-CSF 250 ?g/day for 7 doses prior to marrow harvest. In addition to combination of CsA, MTX, ATG and Mycophenolate mofetil for GVHD prophylaxis, Simulect was administered to prevent severe GVHD. A total 40 mg Simulect was given in two doses of 20 mg each by 30 min intravenous infusion on 2 h before transplantation and day 4 after transplantation.Results All patients were engrafted. 100 % donors hematopoietic cells after transplantation was determined by cytogenetic evidence analysis. None developed the Ⅱ-Ⅳ acute GVHD. Eight patients could be evaluated for chronic GVHD. All experienced chronic GVHD confined to the skin. The median follow-up duration was 14 months (range 12～20 months). One patient died from CMV infection on 3 months and one patient died from disease relapse on 14 months. The remaining 7 patients were survived in disease free situation.Conclusion The use of Simulect in haploidentical bone marrow transplantation is effective on preventing acute severe GVHD and improving disease-free survival.
